AACR Announces 2024 Distinguished Public Service Award Recipients
PHILADELPHIA – The American Association for Cancer Research (AACR) will present the 2024 AACR Distinguished Public Service Award for...
PHILADELPHIA – The American Association for Cancer Research (AACR) will present the 2024 AACR Distinguished Public Service Award for...
SAN ANTONIO – Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the...
SAN DIEGO – Survivors of childhood cancer who consumed more total sugar, added sugar, and sugar-sweetened beverages had more...
Most were able to conceive and more than 60 percent gave birth SAN ANTONIO – Breast cancer patients who...
PHILADELPHIA – The MEK inhibitor trametinib (Mekinist) was an effective treatment for pediatric patients with relapsed or refractory juvenile...
SAN DIEGO – Certain proteogenomic signatures in the prostate cancers of men of African and European ancestries were associated...
“SAN ANTONIO – Patients with early-stage breast cancer who had cancer detected in a sentinel lymph node biopsy had...
PHILADELPHIA – Lower levels of cancer aneuploidy were associated with more favorable outcomes after immune checkpoint inhibition in patients...
ORLANDO, Fla. – The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated...
ORLANDO, Fla. – Adjuvant therapy with atezolizumab (Tecentriq) and bevacizumab (Avastin) increased recurrence-free survival of patients with hepatocellular carcinoma...
Results are from a median follow-up of three years SAN DIEGO – An adjuvant treatment regimen that included autogene...
Patients were pre- or perimenopausal with hormone receptor-positive, HER2-negative tumors SAN ANTONIO – In patients with hormone receptor-positive, HER2-negative,...
PHILADELPHIA — Patients with metastatic melanoma that had relapsed on anti-PD-1 therapies or BRAF/MEK inhibitors did not respond as...
SAN ANTONIO – The next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, compared with fulvestrant (Faslodex), in...
SAN ANTONIO – A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free survival...
Results are from a five-year follow-up; long-term study is needed SAN ANTONIO – Almost all postmenopausal patients aged 50-69...
PHILADELPHIA – ADCT-402, an investigational antibody-drug conjugate, showed signs of clinical activity in patients with relapsed/refractory B-cell non-Hodgkin lymphoma,...
Awardees to be recognized at the AACR Annual Meeting 2022 in New Orleans PHILADELPHIA — The American Association for...
PHILADELPHIA – Victoria’s Secret, Pelotonia, and the American Association for Cancer Research (AACR) today announced the recipients of The...
New article in Clinical Cancer Research lists best practices, novel statistical methods, and suggestions for improving benefit-risk assessments PHILADELPHIA...
Adjuvant T-DM1 improved invasive disease-free survival (IDFS) in patients with HER2-positive early breast cancer with residual invasive disease at...
“SAN ANTONIO – Data from the NRG (NSABP B-39/RTOG 0413) trial indicated that ipsilateral breast tumor recurrence (IBTR) rates...
SAN ANTONIO – Extended follow-up data from the phase III monarchE trial showed that adding the cyclin-dependent kinase (CDK)...
PHILADELPHIA – A HER2-targeted antibody-drug conjugate, fam-trastuzumab deruxtecan-nxki (Enhertu), showed signs of clinical activity in multiple non-breast/non-gastric cancer types,...
PHILADELPHIA – Incidence and severity of neurological side effects from chimeric antigen receptor (CAR) T-cell therapy were higher in...
The epigenomic signature is evident prior to CD19-targeted CAR T-cell treatment NEW ORLEANS – Acute lymphoblastic leukemia (ALL) cells...
Second- and third-generation individuals living in Los Angeles had a 35 and 61 percent higher risk, respectively, than those...
PHILADELPHIA – Intravenous immunoglobulin (IVIg) reduced the risk of severe infections by 90% in patients with multiple myeloma undergoing...
An mRNA vaccine was combined with CAR T cells that target tumor cells expressing the CLDN6 antigen NEW ORLEANS...
SAN ANTONIO – The use of circulating tumor cell (CTC) count to guide the choice between chemotherapy and endocrine...